AstraZeneca stock outlook: Support pressure builds amid seller control

Traders Union
All News
Financial News
AstraZeneca slides 1.37% after trial miss

Highlights

AstraZeneca and Ionis' Wainua failed its primary endpoint in the Cardio-TTRansform trial, undermining pipeline confidence and future cardiovascular revenue prospects.
Pipeline setbacks weigh more heavily on near-term outlook than AstraZeneca's COPD drug acquisition from Sino Biopharmaceutical, limiting positive catalysts.
AstraZeneca trades below key moving averages with strong bearish momentum, expecting to range between GBX11,723 and GBX13,592 with high downside risk.

Pipeline setback as failed trial outweighs limited new asset impact

AstraZeneca and Ionis reported that the Cardio-TTRansform trial for Wainua (eplontersen) in transthyretin amyloid cardiomyopathy did not meet its primary endpoint, with the antisense drug failing to outperform placebo on key cardiovascular outcomes, as stated by Asianbiotechiesinabar Substack. This unsuccessful clinical result puts near-term pressure on pipeline confidence and expectations for expanding cardiovascular revenues. While AstraZeneca also acquired rights to a dual-mechanism COPD drug from Sino Biopharmaceutical that matches the approach of a recent FDA-approved asset, according to Medcitynews, the immediate impact of this move is limited by the more significant trial setback.

Oversold momentum and strong sell signals as support is tested

AZN is currently trading below the MA-20 at GBX13,153 and MA-50 at GBX13,825 on the hourly chart, as well as under the MA-200 at GBX13,786 on the daily timeframe. The Ichimoku Kijun at GBX13,354 now establishes immediate resistance, with the lower bound of support seen at GBX11,723. Technical momentum is severely negative, with the Moving Average Convergence Divergence (MACD) indicating a strong sell bias and the Average Directional Index (ADX) reflecting weak buying strength. The Relative Strength Index (RSI) sits at a deeply oversold 27.05 (Sell), the Stochastic RSI is also deeply oversold, the Commodity Channel Index (CCI) flags ongoing selling, and Bull/Bear Power highlights strong intraday seller dominance. The Awesome Oscillator confirms the prevailing downtrend.

Rangebound trading likely as negative bias and downside risk persist

Over the coming days, AZN is forecast to trade within the GBX11,723 to GBX13,592 volatility band relative to current levels. The probability of a sustained upward move is considered very low given the sharply negative indicator readings, while downside risk is elevated. The baseline scenario expects the price to move sideways within this corridor; further losses could develop if support at GBX11,723 is broken, whereas a rebound would require a sustained move above the immediate resistance at GBX13,354.

Anton Kharitonov, analyst at Traders Union, sees persistent technical weakness in AstraZeneca following the failed Wainua trial. He believes the news flow continues to weigh on sentiment and pipeline credibility. Downside risk remains high as long as the price trades below key resistance. "My base case is for sideways or lower movement unless GBX13,354 is decisively reclaimed."

Earlier, analysts noted that AstraZeneca’s shares were facing persistent downside risk after the failure of its Phase III CARDIO-TTRansform trial for Wainua. The latest technical signals reinforce this negative outlook, with attention now focused on whether AZN can defend support at GBX11,723 or risk further declines if that level fails to hold.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.